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risk group, ﬁnally became a high risk patient. There was a change in PTV and RT dose in 19.2% of patients. Based in MRI ﬁndings,
we changed the decision of treating with HT in 11.5% of patients. Postoperative RT: 33.3% pelvic relapses were diagnosed with
MRI, which inﬂuenced the decision of treatment. In summary, MRI signiﬁcantly inﬂuenced our clinical practice, changing our
treatment in 31.7% of patients.
Conclusion. 3T functional MRI provides an optimal staging for prostate cancer. Its routine use might represent signiﬁcant changes
in the management of such patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.807
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Purpose/objectives. Higher radiation dose levels have been shown to be associated with improved tumor-control outcomes in
localized PCa pts. We previously (SEOR, 2007) presented our preliminary results of escalating doses with 3Dc-EBRT in localized
PCa pts. The aim of this study is to updated long-term results and to identify predictors of biochemical, local control, survival
and toxicity outcomes for pts with clinically localized PCa treated with escalating 3Dc-EBRT.
Methods/materials. From 2003 to 2005 a total of 339 pts diagnosed with cT1–T4 localized PCa were analyzed. Prescription dose to
prostate was 72Gy for low, 74Gy and 6 months of androgen deprivation therapy (ADT) for intermediate, and 76Gy (46Gy to pelvis)
and 2-year of ADT for high-risk. Factors associated to biochemical, local control, survival and toxicity were analysed. Estimates
of survival were determined using Kaplan–Meier methods. Unadjusted and adjusted hazard ratios were calculated using the Cox
regression model.
Results. Mean age was 70 years (range 56–84 years). Pts were staged as low, 60 pts (18%), intermediate, 102 pts (30%) and high-risk
177 pts (52%). A total of 254 pts (75%) received ADT, and 149 pts (44%) received pelvic radiation. Mean rectal and bladder doses
were 49.8Gy and 44.6Gy, respectively. Rectal and bladder constraints (Vr50 and Vb50) were not met in 17% and 34%, respectively.
Biochemical failure (Phoenix deﬁnition) was observed in 7 pts (12%) for low, 10 pts (10%) for intermediate, and 30 pts (17%) for
high-risk. With a median follow-up of 7.28 years (range 1.4–15 years), the 10-year OS and BRFS was 79% and 80%, respectively.
The 10-year BRFS for low, intermediate and high-risk group was 77%, 87% and 76.5% (p>0.05). On multivariate analysis, initial
PSA 10–20ng/ml (p 0.003), Gleason score≥7 (p 0.001), and nadir PSA>0.5ng/ml post-RT (p 0.002) were strongly associated with
biochemical failure. Onmultivariate analysis, time to relapse<24months (p 0.001)were associatedwithworseOS.Onmultivariate
analysis, Gleason score 3+4/4+3 (p 0.003) and time to relapse<24 months (p 0.001) were associated with death due to PCa. There
were not observed any grade 4 or 5 rectal or bladder toxicities (CTCv3).
Conclusions. At 10-year, adapted dose escalation 74Gy and 76Gy 3Dc-EBRT were consistently associated with high biochemical
control and overall survival in intermediate and high-risk PCa pts. Higher Gleason score≥7, nadir psa>0.5ng/ml post-RT, time
to relapse<24 months are strong predictors of biochemical failure, worse OS and increased death due to PCa.
http://dx.doi.org/10.1016/j.rpor.2013.03.808
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Introduction. In prostate cancer (PC) higher biologically effective dose (BED) may be delivered with very conformal techniques like
combined treatment with external beam radiotherapy (EBRT) and boost with high-dose-rate brachytherapy (HDR-BT).
Objectives. Analysis of our ten years experience with EBRT combined with boost with HDR-BT in PC.
Materials and methods. Between June 2002 to December 2011, 648 patients with localized PC were treated using EBRT and boost
with HDR-BT. Median age 71 years. Classiﬁcation by risk groups: 21 (3.1%) low, 337 (52.1%) intermediate and 290 (44.8%) high risk.
All patients received EBRT to prostate and seminal vesicles (median dose of 57.68Gy) and boost with HDR-BT (median dose of
9.73Gy); 320 (49.4%) patients received elective pelvic radiotherapy. The median BED was 200.4Gy. The median values for prostate
volume was 27.32 cm3 and V100=93.3%. BT-planning was performed with tomography images in 347 (53.6%) and in real time
with ultrasound images (Swift) in 301 (46.4%) patients. Androgen blockade 80.9% of patients. We analyzed predictive factors
in relation with tumor (risk group, perineural invasion), implant (prostate volume, number of needles, V100) and treatment
(duration, sequences, BED and planning with tomography vs Swift).
Results. With a median follow up of 61.1 months, the 5 and 10 years actuarial rates of biochemical failure free survival (BFFS) and
disease free survival other than BFFS (DFS) were 86.6%/96.4% and 69.6%/72.6%. Rates of genitourinary acute and chronic toxicities
